“…Enhancer transcription is considered the best molecular indicator of enhancer activity in developmental processes (Wu et al, 2014;Arner et al, 2015;Kim et al, 2015;Carullo et al, 2020;Sartorelli and Lauberth, 2020) and cancers (Chen and Liang, 2020). There has been uncertainty about whether the resulting eRNAs are byproducts of TF binding at enhancers or are integral to enhancer action (Li et al, 2016;Schoenfelder and Fraser, 2019), but the evidence is now strongly in favor of the latter, although it is also clear that the act of transcription itself modulates enhancer activity (Pande et al, 2018;Morf et al, 2020;Pande et al, 2020). While genetic analysis by enhancer deletion may not distinguish between the loss of cis-acting DNA regulatory elements and transacting elncRNAs (Gao et al, 2020;Andergassen and Rinn, 2021), more incisive strategies such as the insertion of polyA transcription termination sites, removal of elncRNA exons, siRNA-and CRISPRi/ Cas13-directed RNA knockdown have shown that elncRNAs are required for enhancer function in diverse contexts (Maass et al, 2012;Li et al, 2013;Melo et al, 2013;Lam et al, 2014;Paralkar et al, 2014;Sun et al, 2014;Xiang et al, 2014;Yin et al, 2015;Yang et al, 2016;Isoda et al, 2017;Cajigas et al, 2018;Groff et al, 2018;Fatima et al, 2019;Lewandowski et al, 2019;Allou et al, 2021;Andergassen and Rinn, 2021;Cajigas et al, 2021;Setten et al, 2021;Zibitt et al, 2021).…”